Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
Do you use an LAD constraint in the setting of BID thoracic radiation for SCLC?
Related Questions
How do you assess whether a patient will be a good DIBH candidate for lung or abdomen treatments?
For NSCLC patients treated with neoadjuvant chemoimmunotherapy and surgery with ypN2 disease, what factors would cause you to recommend PORT?
How do you approach a patient with stage IIA non-small cell lung cancer who received SBRT?
What is your approach to radiographically suspicious lung nodules for which initial biopsy was negative for malignancy?
For ultracentral lung cancer abutting the heart, what dose constraints would you use for the heart and bronchus if using 10 fraction ultrahypofractionation?
Is there a chest wall constraint you typically use for 60 Gy in 15 fraction NSCLC treatment?
How are you incorporating Tumor Treating Fields for locally progressive/metastatic NSCLC, if at all?
In a patient who underwent cryoablation for early NSCLC, is there a role for giving preemptive further local therapy?
What are your top takeaways in Thoracic Cancers from ASTRO 2024?
Do you perform EBUS-TBNA for staging in patients with biopsy proven malignant lung nodules with no lymphadenopathy on CT chest and PET scan?
